Compound Bone Peptide for Injection - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510241411

Publication Date:

October 28, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Compound bone peptide preparation, wherein, the compound bone peptide preparation is produced by mixing bone peptide extracting solution and scorpion extracting solution, performing acid treatment and alkali treatment to the mixed solution in sequence, regulating the pH value of the mixed solution after the alkali treatment is performed to be neutral, and ensuring the mixed solution with neutral pH value to contact with active carbon. The compound bone peptide preparation of the invention can be produced to be small capacity injection and freeze-dried powder injection. Compared with the prior method that the bone peptide extracting solution and the scorpion extracting solution are respectively and singly treated and then mixed, the compound bone peptide preparation provided by the invention is produced through acid precipitation, alkali precipitation and active carbon adsorption to the mixed solution of the bone peptide extracting solution and the scorpion extracting solution, can effectively remove impurity generated through the interaction because of the mixing of the bone peptide extracting solution and the scorpion extracting solution, and thereby obviously improving the clarity and reducing the injection irritability of the compound bone peptide preparation (namely improving the injection compliance).
The global market for Compound Bone Peptide for Injection was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Compound Bone Peptide for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Compound Bone Peptide for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Compound Bone Peptide for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Compound Bone Peptide for Injection include Jiangshi Pharma, Zhitong Biopharma and Xinbai Pharmaceutical, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Compound Bone Peptide for Injection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Compound Bone Peptide for Injection by region & country, by Type, and by Application.
The Compound Bone Peptide for Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Compound Bone Peptide for Injection.
麻豆原创 Segmentation
By Company
Jiangshi Pharma
Zhitong Biopharma
Xinbai Pharmaceutical
Segment by Type:
Intramuscular Injection
Intravenous Drip
Segment by Application
Rheumatism
Rheumatoid Arthritis
Osteoporosis
Cervical spondylosis
Post-fracture healing
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Compound Bone Peptide for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Compound Bone Peptide for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Compound Bone Peptide for Injection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Compound Bone Peptide for Injection Product Introduction
1.2 Global Compound Bone Peptide for Injection 麻豆原创 Size Forecast
1.2.1 Global Compound Bone Peptide for Injection Sales Value (2019-2030)
1.2.2 Global Compound Bone Peptide for Injection Sales Volume (2019-2030)
1.2.3 Global Compound Bone Peptide for Injection Sales Price (2019-2030)
1.3 Compound Bone Peptide for Injection 麻豆原创 Trends & Drivers
1.3.1 Compound Bone Peptide for Injection Industry Trends
1.3.2 Compound Bone Peptide for Injection 麻豆原创 Drivers & Opportunity
1.3.3 Compound Bone Peptide for Injection 麻豆原创 Challenges
1.3.4 Compound Bone Peptide for Injection 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Compound Bone Peptide for Injection Players Revenue Ranking (2023)
2.2 Global Compound Bone Peptide for Injection Revenue by Company (2019-2024)
2.3 Global Compound Bone Peptide for Injection Players Sales Volume Ranking (2023)
2.4 Global Compound Bone Peptide for Injection Sales Volume by Company Players (2019-2024)
2.5 Global Compound Bone Peptide for Injection Average Price by Company (2019-2024)
2.6 Key Manufacturers Compound Bone Peptide for Injection Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Compound Bone Peptide for Injection Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Compound Bone Peptide for Injection
2.9 Compound Bone Peptide for Injection 麻豆原创 Competitive Analysis
2.9.1 Compound Bone Peptide for Injection 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Compound Bone Peptide for Injection Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Compound Bone Peptide for Injection as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Intramuscular Injection
3.1.2 Intravenous Drip
3.2 Global Compound Bone Peptide for Injection Sales Value by Type
3.2.1 Global Compound Bone Peptide for Injection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Compound Bone Peptide for Injection Sales Value, by Type (2019-2030)
3.2.3 Global Compound Bone Peptide for Injection Sales Value, by Type (%) (2019-2030)
3.3 Global Compound Bone Peptide for Injection Sales Volume by Type
3.3.1 Global Compound Bone Peptide for Injection Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Compound Bone Peptide for Injection Sales Volume, by Type (2019-2030)
3.3.3 Global Compound Bone Peptide for Injection Sales Volume, by Type (%) (2019-2030)
3.4 Global Compound Bone Peptide for Injection Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rheumatism
4.1.2 Rheumatoid Arthritis
4.1.3 Osteoporosis
4.1.4 Cervical spondylosis
4.1.5 Post-fracture healing
4.1.6 Others
4.2 Global Compound Bone Peptide for Injection Sales Value by Application
4.2.1 Global Compound Bone Peptide for Injection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Compound Bone Peptide for Injection Sales Value, by Application (2019-2030)
4.2.3 Global Compound Bone Peptide for Injection Sales Value, by Application (%) (2019-2030)
4.3 Global Compound Bone Peptide for Injection Sales Volume by Application
4.3.1 Global Compound Bone Peptide for Injection Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Compound Bone Peptide for Injection Sales Volume, by Application (2019-2030)
4.3.3 Global Compound Bone Peptide for Injection Sales Volume, by Application (%) (2019-2030)
4.4 Global Compound Bone Peptide for Injection Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Compound Bone Peptide for Injection Sales Value by Region
5.1.1 Global Compound Bone Peptide for Injection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Compound Bone Peptide for Injection Sales Value by Region (2019-2024)
5.1.3 Global Compound Bone Peptide for Injection Sales Value by Region (2025-2030)
5.1.4 Global Compound Bone Peptide for Injection Sales Value by Region (%), (2019-2030)
5.2 Global Compound Bone Peptide for Injection Sales Volume by Region
5.2.1 Global Compound Bone Peptide for Injection Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Compound Bone Peptide for Injection Sales Volume by Region (2019-2024)
5.2.3 Global Compound Bone Peptide for Injection Sales Volume by Region (2025-2030)
5.2.4 Global Compound Bone Peptide for Injection Sales Volume by Region (%), (2019-2030)
5.3 Global Compound Bone Peptide for Injection Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Compound Bone Peptide for Injection Sales Value, 2019-2030
5.4.2 North America Compound Bone Peptide for Injection Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Compound Bone Peptide for Injection Sales Value, 2019-2030
5.5.2 Europe Compound Bone Peptide for Injection Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Compound Bone Peptide for Injection Sales Value, 2019-2030
5.6.2 Asia Pacific Compound Bone Peptide for Injection Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Compound Bone Peptide for Injection Sales Value, 2019-2030
5.7.2 South America Compound Bone Peptide for Injection Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Compound Bone Peptide for Injection Sales Value, 2019-2030
5.8.2 Middle East & Africa Compound Bone Peptide for Injection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Compound Bone Peptide for Injection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Compound Bone Peptide for Injection Sales Value
6.2.1 Key Countries/Regions Compound Bone Peptide for Injection Sales Value, 2019-2030
6.2.2 Key Countries/Regions Compound Bone Peptide for Injection Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Compound Bone Peptide for Injection Sales Value, 2019-2030
6.3.2 United States Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Compound Bone Peptide for Injection Sales Value, 2019-2030
6.4.2 Europe Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Compound Bone Peptide for Injection Sales Value, 2019-2030
6.5.2 China Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Compound Bone Peptide for Injection Sales Value, 2019-2030
6.6.2 Japan Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Compound Bone Peptide for Injection Sales Value, 2019-2030
6.7.2 South Korea Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Compound Bone Peptide for Injection Sales Value, 2019-2030
6.8.2 Southeast Asia Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Compound Bone Peptide for Injection Sales Value, 2019-2030
6.9.2 India Compound Bone Peptide for Injection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Compound Bone Peptide for Injection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Jiangshi Pharma
7.1.1 Jiangshi Pharma Company Information
7.1.2 Jiangshi Pharma Introduction and Business Overview
7.1.3 Jiangshi Pharma Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Jiangshi Pharma Compound Bone Peptide for Injection Product Offerings
7.1.5 Jiangshi Pharma Recent Development
7.2 Zhitong Biopharma
7.2.1 Zhitong Biopharma Company Information
7.2.2 Zhitong Biopharma Introduction and Business Overview
7.2.3 Zhitong Biopharma Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Zhitong Biopharma Compound Bone Peptide for Injection Product Offerings
7.2.5 Zhitong Biopharma Recent Development
7.3 Xinbai Pharmaceutical
7.3.1 Xinbai Pharmaceutical Company Information
7.3.2 Xinbai Pharmaceutical Introduction and Business Overview
7.3.3 Xinbai Pharmaceutical Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Xinbai Pharmaceutical Compound Bone Peptide for Injection Product Offerings
7.3.5 Xinbai Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Compound Bone Peptide for Injection Industrial Chain
8.2 Compound Bone Peptide for Injection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Compound Bone Peptide for Injection Sales Model
8.5.2 Sales Channel
8.5.3 Compound Bone Peptide for Injection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Jiangshi Pharma
Zhitong Biopharma
Xinbai Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.